Webinar
Ann Theodore Foundation Sarcoidosis Inhibitor of mTOR, 2026: Information Session
SHARE
The Ann Theodore Foundation (ATF), in partnership with Milken Institute Strategic Philanthropy’s Science Philanthropy Accelerator for Research and Collaboration (SPARC), is accepting applications from independent researchers for a new funding program, ATF Sarcoidosis Inhibitor of mTOR (SIM), by Monday, April 20, 2026.
Watch the informational session for potential applicants, which was held Thursday, February 26.
ATF-SIM will award one grant to support a two-year, investigator-initiated Phase 2 clinical trial to test the efficacy of mTOR inhibitors in treating cutaneous sarcoidosis.
The awarded team will be eligible for up to $250,000 per year in direct costs, plus 15 percent in indirect costs, totaling $287,500 per year for a total of $575,000 over two years.
Please see the full Request for Proposals for additional information.
SHARE
Related Content
-
Uterine Leiomyosarcoma: A Giving Smarter Guide
This Giving Smarter Guide describes the current state of research, clinical practice, and treatment approaches for uterine leiomyosarcoma (uLMS) and identifies critical areas where philanthropy can significantly advance scientific knowledge...Read ReportIP
-
Milken Institute, Ann Theodore Foundation Launch New Grant to Support Clinical Trial for Potential Sarcoidosis Treatment
February 20, 2026 (Washington, DC)—The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a future...Read Article -
Request for Proposals: Ann Theodore Foundation Sarcoidosis Inhibitor of mTOR (SIM) Trial
The Ann Theodore Foundation (ATF) is launching a new funding program to support the study of repurposed mechanistic target of rapamycin (mTOR) inhibitors as treatments for cutaneous sarcoidosis. This program will be executed in partnership...Read Article -
Request for Proposals: Ann Theodore Foundation Learning Opportunities in Medicine and Sarcoidosis
The ATF-LOMAS is now accepting applications for awards of up to $100,000 per year for two-year research projects led by early career investigators who seek to increase the foundational understanding of sarcoidosis through projects focused...Read Article -
Kissick Family Foundation, Milken Institute Announce $3 Million in Funding for Frontotemporal Dementia Research
September 25, 2024 (Washington, DC)—The Kissick Family Foundation Frontotemporal Dementia (FTD) Grant Program, in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), today announced...Read Article -
Frontotemporal Dementia Giving Smarter Guide
Frontotemporal dementia (FTD) refers to a family of neurodegenerative conditions that cause changes in behavior, mood, executive function, language, memory, and motor function. FTD is widely believed to be underdiagnosed and undercounted...Read Report
MM
-
Ann Theodore Foundation Breakthrough Sarcoidosis Initiative Grant Awardees 2023
The Ann Theodore Foundation and the Milken Institute are pleased to announce the five research teams selected to receive funding for research to advance understanding of the underlying biology of sarcoidosis, a poorly understood immune...Read Article -
Request for Proposals: ALS Breakthrough Research Fund
Tambourine is launching the ALS Breakthrough Research Fund. This new fund will support basic and discover-focused research in amyotrophic lateral sclerosis (ALS).Read Article